Qiu-Yan Zhang

Qiu-Yan Zhang

Auto-generated profile, based on publicly available information

Qiu-Yan Zhang

Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Phytomedicine
Verified
Journal Article
Closed access
WZWeiwei Zhu
Weiwei Zhu
WLWu Luo
Wu Luo
JHJibo Han
Jibo Han
QZQiuyan Zhang
Qiuyan Zhang
LJLijun Ji
Lijun Ji
YWYi Wang
Yi Wang

22 September 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
QZQiu-Yan Zhang
Qiu-Yan Zhang
SXSu-Jing Xu
Su-Jing Xu
JQJianchang Qian
Jianchang Qian
LYLi-Bin Yang
Li-Bin Yang
PCPeng-Qin Chen
Peng-Qin Chen
GLGuang Liang
Guang Liang
Emerging evidence shows that chronic inflammation mediated by toll-like receptors (TLRs) contributes to diabetic nephropathy. Myeloid differentiation primary-response protein-88 (MyD88) is an essential adapter protein of all TLRs except TLR3 in innate immunity. It is unclear whether MyD88 could be a therapeutic target for diabetic nephropathy. Here, we used a new small-molecule MyD88 inhibitor, LM8, to examine the pharmacological inhibition of MyD88 in protecting kidneys from inflammatory injury in diabetes. We showed that MyD88 was significantly activated in the kidney of STZ-induced type 1 diabetic mice in tubular epithelial cells as well as in high glucose-treated rat tubular epithelial cells NRK-52E. In cultured tubular epithelial cells, we show that LM8 (2.5−10 μM) or MyD88 siRNA attenuated high-concentration glucose-induced inflammatory and fibrogenic responses through inhibition of MyD88-TLR4 interaction and downstream NF-κB activation. Treatment with LM8 (5, 10 mg/kg, i.g.) significantly reduced renal inflammation and fibrosis and preserved renal function in both type 1 and type 2 diabetic mice. These renoprotective effects were associated with reduced MyD88-TLR4 complex formation, suppressed NF-κB signaling, and prevention of inflammatory factor expression. Collectively, our results show that hyperglycemia activates MyD88 signaling cascade to induce renal inflammation, fibrosis, and dysfunction. Pharmacological inhibition of MyD88 may be a therapeutic approach to mitigate diabetic nephropathy and the inhibitor LM8 could be a potential candidate for such therapy.